Top Markets
#1 Black Phoenix Black Phoenix +823.38%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +26.27%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.33%
#4 Prom Prom +20.84%
#5 Beam Beam +20.03%
#6 SAFEcoin SAFEcoin +19.77%
#7 Magma Finance Magma Finance +19.58%
#8 Bless Bless +17.25%
#9 pipedog pipedog +16.97%
#10 YFSX YFSX +16.05%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
株式のランク #5950
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
株価
$45.79
時価総額
$2.33B
変化（1日）
11.43%
変化（1年）
408.10%
国
FR
取引 Nanobiotix S.A. (NANO)

カテゴリー

Healthcare
Nanobiotix S.A.（NANO）の収益
Aug 2026 時点の収益 TTM: 0
Nanobiotix S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Nanobiotix S.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH